Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  ALK-Abelló A/S    ALK B   DK0060027142

ALK-ABELLÓ A/S

(ALK B)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
2086(c) 2088(c) 2090(c) 2084(c) 2126 Last
9 857 7 146 8 582 9 842 17 268 Volume
+1.07% +0.10% +0.10% -0.29% +2.02% Change
More quotes
Financials
Sales 2020 3 512 M 561 M 561 M
Net income 2020 73,1 M 11,7 M 11,7 M
Net Debt 2020 574 M 91,7 M 91,7 M
P/E ratio 2020 314x
Yield 2020 -
Sales 2021 3 948 M 631 M 631 M
Net income 2021 139 M 22,2 M 22,2 M
Net Debt 2021 615 M 98,3 M 98,3 M
P/E ratio 2021 166x
Yield 2021 0,14%
Capitalization 22 750 M 3 632 M 3 637 M
EV / Sales 2020 6,64x
EV / Sales 2021 5,92x
Nbr of Employees 2 405
Free-Float 88,9%
More Financials
Company
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines... 
More about the company
Notations Surperformance© of ALK-Abelló A/S
Trading Rating : Investor Rating :
More Ratings
All news about ALK-ABELLÓ A/S
11/16ALK ABELLÓ A/S : Report on transactions with ALK-Abelló A/S B-shares and associa..
AQ
11/11ALK ABELLÓ A/S : Nine-month interim report (Q3) 2020
AQ
11/11ALK ABELLÓ A/S : Nine-month interim report (Q3) 2020
AQ
11/11Nine-month interim report (Q3) 2020
GL
11/06ALK ABELLÓ A/S : Two new members of ALK's Board of Directors
AQ
11/05ALK ABELLÓ A/S : Release date of nine-month interim report (Q3) 2020 for ALK and..
AQ
11/05ALK ABELLÓ A/S : updates its full-year financial outlook
AQ
11/05ALK ABELLÓ A/S : updates its full-year financial outlook
AQ
11/05ALK updates its full-year financial outlook
GL
08/12Six-month interim report (Q2) 2020
GL
08/05ALK ABELLÓ A/S : Release date of six-month interim report (Q2) 2020 for ALK and ..
AQ
05/20ALK ABELLÓ A/S : Report on transactions with ALK-Abelló A/S B-shares and associa..
AQ
05/11ALK ABELLÓ A/S : Report on transactions with ALK-Abelló A/S B-shares and associa..
AQ
05/06Three-month interim report (Q1) 2020
GL
04/28ALK ABELLÓ A/S : Release date of three-month interim report (Q1) 2020 for ALK an..
AQ
More news
News in other languages on ALK-ABELLÓ A/S
08/13AVIS D'ANALYSTES DU JOUR : ASOS, Avast, BMW, Crédit Agricole, Idorsia, Natixis, ..
08/13A Wall Street, le S&P500 efface le coronavirus
2019AVIS D'ANALYSTES DU JOUR : Bic, BNP Paribas, GTT, Total, Beiersdorf, Glencore, G..
2019STOCK MARKET PARIS : Le piège de Trump se referme sur la Fed
2019AVIS D'ANALYSTES DU JOUR : Airbus, Renault, Valeo, Peugeot, Swisscom, Dassault S..
More news
Stock Trading Strategies
ALK-ABELLÓ A/S - 11/13
The underlying trend is in force again
BUY
More Stock Trading Analysis
Chart ALK-ABELLÓ A/S
Duration : Period :
ALK-Abelló A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALK-ABELLÓ A/S
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 2 259,60 DKK
Last Close Price 2 084,00 DKK
Spread / Highest target 16,4%
Spread / Average Target 8,43%
Spread / Lowest Target -7,39%
EPS Revisions
Managers
NameTitle
Carsten Hellmann President & Chief Executive Officer
Anders Hedegaard Chairman
Sřren Jelert Chief Financial Officer & Executive Vice President
Henrik Hugo Jacobi Executive Vice President-Research & Development
Katja Barnkob Thalund Director
Sector and Competitors
1st jan.Capitalization (M$)
ALK-ABELLÓ A/S27.46%3 632
JOHNSON & JOHNSON-1.37%378 744
ROCHE HOLDING AG-4.28%281 946
PFIZER INC.-6.59%203 437
MERCK & CO., INC.-11.89%202 757
NOVARTIS AG-12.66%200 273